Mission

Amprion revolutionizes diagnosis for brain diseases. Through molecular testing, we help accelerate medical science for personalized medicine. 

Scientific Journey

As a pioneer in Prion Detection Science™️, we believe precision medicine is the new frontier. We strive to positively impact brain disease diagnosis and treatment as the world population ages rapidly. See our evolving scientific journey below.

2007
2007

Once Upon A Time

Neuroscientist Claudio Soto teams up with molecular pathologist Dr. Russ Lebovitz to detect prions, aka misfolded proteins, to eliminate mad cow disease.

Watch Our Origin Story
2010
2010

The Pivot

As mad cow disease dissipates, the team pivots, asking: Is there a parallel between misfolded proteins in mad cow disease and human brain disorders?

Watch Video To Learn More
2013
2013

Aha Moment!

Dr. Soto proves there is a similarity and develops an assay to detect misfolded Abeta, a biomarker found in most Alzheimer’s patients.

Learn About Our Science
2014
2014

Amprion Was Born

The team expands research to detect other misfolded proteins, including Synuclein and Tau. 

Watch The Amprion Story
2015
2015

Our Mission

Revolutionize molecular testing to help doctors diagnose brain diseases accurately. 

How Amprion Helps Doctors
2017
2017

Our Science

Amprion expands its lab, conducting further scientific research using its proprietary Prion Detection Science™️.

How We Help Accelerate Drug R&D
2018
2018

Scientists At Work

The company establishes a state-of-the-art clinical lab run by dedicated scientists and experts, not to mention tireless bots when humans are off the clock.

Learn How Our Science Works
2019
2019

FDA Breakthrough Designation

The US FDA awards Amprion Breakthrough Device Designation for detecting misfolded Synuclein, a key brain disease biomarker.

Watch FDA Breakthrough Designation
Feb 2020
Feb 2020

Breakthrough Publishing

Dr. Soto published a research article in Nature. 

Learn More
2020
2020

Covid Push For CLIA

Team Amprion, standing 6-feet apart, worked through Covid and reached a significant milestone. We achieved CLIA approval for our clinical lab.

View CLIA Certificate
2021
2021

SYNTap Test Commercial Rollout

Our first biomarker test helps doctors diagnose Parkinson’s, and Lewy Body Dementia by detecting misfolded Synuclein in CSF. This test is developed and validated by a licensed physician pathologist in our CAP-accredited clinical laboratory.

Discover Here